SB 1047 extends neurodegenerative registry authority
Oct 4, 2026 edition · GC-2026-0238 · Published 2026-10-04 · Version 2 · Final
SB 1047 adds frontotemporal degeneration to California’s neurodegenerative registry system and extends the chapter until January 1, 2032. Reporting remains linked to CDPH designation, prescribed formats, advance notification and available implementation funding.
What happened
California enacted SB 1047 on September 30, amending Health and Safety Code sections 103871 and 103871.2. CDPH’s neurodegenerative data-collection system must include frontotemporal degeneration, alongside ALS, and the statutory category may include other dementias in addition to the other listed diseases. The law extends the chapter’s repeal date to January 1, 2032. The system remains a means of determining incidence and prevalence rather than a new clinical diagnostic standard. The enactment is the event reported here; the applicable commencement of these provisions must be confirmed separately.
The reporting framework directs CDPH to designate the diseases required to be reported and to notify physicians, hospitals and the Medical Board at least 90 days before requiring information. Providers diagnosing or treating a covered case must report it in the department’s prescribed format. If a facility does not report in that format, the department can obtain and report the information and recover its costs; willful refusal of the specified record access can draw daily civil penalties. Collected information remains confidential except as the chapter provides, and implementation is limited to available funding. The enactment alone does not establish that every FTD case became immediately reportable on signing.
Scope and timing
- Authority status
- Final
- Applicability
- Potentially applicable
- Audience
- Health systems, Provider networks, Health-tech
- Jurisdiction
- California
Why it matters
Neurology and reporting teams need the actual CDPH designation and specifications to decide which cases and records enter the registry. Confidentiality, record access and format requirements are distinct from merely adding a disease name to the statute.
Recommended action
Confirm the applicable commencement before treating the new provisions as current duties. Prepare the following for implementation at that commencement: Track CDPH designation and 90-day notification materials and compare them with registry reporting workflows. Confirm the prescribed format, responsible team and record-access arrangements before treating FTD as a newly active reporting requirement. Keep implementation funding and confidentiality conditions in the scope review.
Sources
- SB1047 enacted final textOfficial · California Legislature · 2026-09-30 · Source review 2026-10-05
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Compliance Sweep report →